Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $86

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $81 to $86.
byBenzinga Newsdesk
July 20, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $81 to $86.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0